Articles tagged with Breast Cancer
A randomized controlled trial found that conjugated equine estrogen increased the risk of benign proliferative breast disease by more than two-fold. Women taking estrogen supplements had 155 cases of benign disease compared to 77 in the placebo group.
Researchers discovered a molecular pathway underlying low-grade forms of brain tumor known as astrocytoma, suggesting new therapeutic targets. Additionally, studies revealed that microRNAs regulate female mouse fertility by controlling the functioning of the corpus luteum, which is essential for pregnancy.
Research suggests that genistein in soy foods reduces the risk of breast cancer by controlling cell growth and death in young women. The exact mechanism is not yet fully understood, but studies suggest a link between soy consumption during puberty and reduced breast cancer risk.
A study by researchers at the University of Mississippi found that consuming green tea's EGCG significantly inhibits breast tumor growth and angiogenesis in female mice. The results suggest that EGCG may provide protection against breast cancer by targeting tumor blood vessels and cells.
Researchers discovered T-cadherin's role in promoting tumor vascularization, slowing down tumor growth and improving survival. However, the absence of this protein also led to more aggressive disease in the long run.
A recent study found that the human breast tumor microenvironment can prime cells for metastasis, particularly to the lungs. Researchers discovered a correlation between TGFß exposure and increased risk of lung cancer in ER- tumors.
A study of over 3,000 adult women found that those with the highest intake of choline had a 24% lower risk of developing breast cancer. Choline is an essential nutrient found in eggs, coffee, and skim milk, and increasing its intake may be particularly important for women.
A recent study found that patients who received a discussed breast reconstruction had higher odds of undergoing the procedure. Researchers recommend improving communication between physicians and patients to reduce disparities in breast reconstruction rates.
A new study combines clinical characteristics with genomic profiles to predict breast cancer prognosis and guide treatment. By matching the right drugs with the right patients, researchers aim to provide more personalized treatment strategies.
A study integrating genetic information with breast cancer risk factors refines estimates of relapse-free survival and predicts response to chemotherapy. Gene expression signatures provide valuable insights into breast cancer heterogeneity, enabling more precise clinical outcomes.
Researchers at the University of Missouri found that synthetic hormone replacement therapy can promote breast cancer growth, but an antibody and small molecular drug may prevent tumor cell expansion. The study suggests a potential link between hormone replacement therapy and breast cancer progression.
A comprehensive review of breast cancer research identifies key gaps in treatment and patient care, calling for increased attention on prevention, detection, and spread. The charity Breast Cancer Campaign is already funding innovative projects to fill these gaps and improve survival rates.
A new study has found that hormone replacement therapy (HRT) increases the risk of breast cancer recurrence in women who have survived breast cancer. The HABITS trial, which followed over 200 breast cancer survivors for four years, found that HRT significantly increased the risk of disease recurrence.
The use of sentinel lymph node biopsy (SLNB) increased substantially from 1998 to 2005, but disparities persist in access to the procedure. Non-white women, older women, and those living in poorer areas were less likely to receive SLNB than their counterparts, highlighting uneven access to this less-invasive breast cancer staging test.
A new study found that while MRI has a high false positive rate, it still detects genuine breast cancer cases effectively. However, the rate of false positives does not impact a woman's decision to undergo prophylactic mastectomy.
Researchers at Harvard Medical School have identified proteins that promote tumor growth in certain types of cancer, including breast and ovarian cancer. Targeting these proteins with small molecules may lead to new therapeutic options for patients.
Researchers found that tumour relapse rates were similar between lower dose regimens (50Gy, 41.6Gy, 39Gy) and the standard schedule. Both photographic and patient self-assessments suggested lower late adverse effects after these lower dose regimens.
Researchers found unsuspected treatable tumors in Li-Fraumeni syndrome patients using full-body PET/CT scanning. The study suggests that periodic scans could catch more tumors at a curable stage, but further studies are needed to confirm the benefits and risks.
A new study found that family discussions about cancer history significantly impact knowledge and attitudes about genetic counseling and testing for moderate-risk women. Women who discussed their family's cancer history with relatives had greater knowledge and more positive attitudes towards testing.
A study by the University of Chicago's Center for Interdisciplinary Health Disparities Research links early onset breast cancer in black women to neighborhood conditions, including social isolation and stress. The research aims to inform policy makers on creating cost-effective interventions to reduce women's vulnerability.
Women with breast cancer who are obese experience more aggressive disease, including higher rates of inflammatory breast cancer and increased risk of recurrence. Obesity can lead to weight gain during treatment, further increasing the risk of recurrence.
A study found two gene variants in the AKAP protein family to be linked to an elevated breast cancer risk, particularly in women from breast cancer families. These variants, located on the AKAP9 gene, were found to increase the risk by 17% and 27% respectively.
Researchers discovered that SATB1 protein promotes tumor growth and metastasis in breast cancer. High levels of SATB1 expression are associated with poor prognosis, and reducing SATB1 can prevent the formation of invasive cells.
Researchers found that COX-2 expression is a marker for cancer development in some benign breast biopsies, with higher levels associated with increased risk. The study's results may lead to targeted treatments using COX-2 inhibiting agents.
A study of Hiroshima and Nagasaki bombing survivors found that radiation exposure in utero and early childhood increases the risk of adult solid cancers. Individuals carrying a rare genetic variant of AKAP9 gene also have an increased risk of breast cancer.
The American Association for Cancer Research (AACR) is honoring world-class cancer researchers for their significant contributions to the fight against cancer. The AACR Awards Program recognizes outstanding achievements in basic cancer research, clinical care, therapeutics, and prevention.
Treatment with letrozole initiated one to seven years after stopping tamoxifen therapy cuts the risk of breast cancer recurrence in half and metastasis by 60%. The chance that a new tumor develops in the unaffected breast is also significantly reduced. These findings suggest aromatase inhibition can still offer preventive benefits.
A new study has demonstrated a lower risk of cardiac toxicity with dose-dense chemotherapy in early-stage HER2-positive breast cancer patients. The regimen, which administers standard doses of chemotherapy agents more frequently, pairs safely with trastuzumab and resulted in only 1.4% cardiac events after 28 months of follow-up.
A comprehensive review of 21 studies covering over 37,000 women found that anti-inflammatory drugs like aspirin may reduce breast cancer risk and provide a useful addition to treatment for existing sufferers
A follow-up study of women who stopped taking hormone therapy after a clinical trial found an increased risk of cancer, with higher rates of invasive breast cancer and other cancers. Cardiovascular events were comparable between the two groups.
A follow-up study of the Women's Health Initiative confirms that long-term use of combination hormone therapy in healthy postmenopausal women increases risks of heart disease, stroke, and blood clots. After stopping hormone therapy, cardiovascular disease risk decreases but overall risks remain high.
Researchers at UCSF have developed a new model for estimating breast cancer risk, incorporating breast density and ethnicity, which is well-calibrated and reasonably accurate across risk factor subgroups. The model may one day be used to calculate a woman's risk for breast cancer during mammograms.
A new guideline for treating dementia emphasizes the importance of individualized assessment and treatment based on a patient's specific medication regimen. Researchers also developed two new blood tests to diagnose latent tuberculosis, finding that one test is more sensitive than traditional methods.
Researchers at Memorial Sloan-Kettering Cancer Center have discovered a new genetic marker that increases breast cancer risk by 1.4 times in women with the DNA variation. The study used genome-wide association mapping to identify a gene locus on chromosome 6 associated with breast cancer risk.
Researchers have identified a new target for cancer therapy by targeting the non-malignant cells surrounding tumors, which can stop tumor growth in mice. This approach has shown promise in reducing tumor size and slowing growth of well-established cancers after a single injection of T cells.
A new study, ALTTO, is testing two targeted medications to treat aggressive breast cancer in 8,000 participants across 50 countries. The trial will compare four different regimens of targeted therapy and provide insights into individualized patient care.
The American Association of Physicists in Medicine celebrates its 50th anniversary, highlighting key contributions of medical physicists to medicine. Medical physicists have developed technologies such as MRI, CT scanning, and PET scanning, which have transformed imaging and cancer treatment.
A Weill Cornell team discovered that EP2 and EP4 receptors play a key role in boosting estrogen production in fat and breast cancer cells. This pathway increases the risk of hormone receptor-positive breast cancer. The study's findings suggest new targets for pharmaceutical research, including drugs that target these receptors.
A new study from the American Cancer Society reveals that breast cancer death rates among African American women are decreasing in only 11 US states and remain flat or increase in at least half. The disparity is attributed to access issues, regional variations in treatment quality, and limited screening services.
Patients with HER2-positive tumours who receive trastuzumab treatment after diagnosing brain metastases have improved survival rates. The study found a correlation between triple receptor status and the incidence of brain metastases, as well as survival time.
A study of 829 Canadian women diagnosed with early breast cancer found that they lost an average of 27% of their typical income during the first 12 months after diagnosis. The researchers also discovered that wage losses were more common among less educated women, those with more serious disease, and those with less social support.
A study of post-menopausal women found that hormone therapy increased the risk of abnormal mammograms and breast biopsies, while also decreasing the effectiveness of these methods for detecting breast cancer. The therapy may delay diagnosis and increase breast density, which can lead to a higher risk of breast cancer.
A recent study published in Archives of Internal Medicine found that combined hormone therapy significantly increases the risk of abnormal mammograms and breast biopsies, compromising their diagnostic performance. The research involved 16,608 post-menopausal women and revealed a four percent greater risk of mammogram abnormalities afte...
Researchers at NIST, NCI, and SAIC developed a new method for detecting HER2 breast cancer using chicken immunoglobulin Y (IgY) antibody tagged with quantum dot. This approach improves the detection of HER2 biomarker by 40-50% compared to existing tests.
Researchers at the MUHC have identified HSP90 as a promising therapeutic target for ocular melanoma. By targeting this protein, it is possible to disrupt multiple cellular functions and block cancer cell reproduction, leading to tumour regression.
A growing body of evidence supports preventive measures for high-risk women, including those with BRCA1 and BRCA2 mutations. Primary care physicians should learn about genetics, take a comprehensive personal and family history to advise patients at increased risk.
Research found that DDT's main metabolite, p,p'-DDE, disrupts hormone-sensitive breast cancer cells by opposing the androgen signalling pathway. This suggests a new mechanism for breast cancer progression, potentially favouring tumour growth in women.
Researchers at Yale School of Medicine have developed a blood test that detects early stage ovarian cancer with 99% accuracy, building on previous work showing 95% effectiveness. The new platform uses six protein biomarkers instead of four, increasing specificity from 95 to 99.4%.
A study found that women with ductal carcinoma in situ (DCIS) have overly optimistic views of their risk of recurrence and invasive breast cancer. Anxiety levels decreased over time, but depression remained low. Clinicians should be aware of these inaccurate perceptions to minimize distress.
A study led by Dana-Farber Cancer Institute researchers found that women with ductal carcinoma in situ (DCIS) often misperceive their risk of recurrence or dying from breast cancer, due to elevated anxiety. This can lead to poor treatment choices and negatively impact emotional well-being and health behaviors.
A study found that breast cancer survivors, especially older women, are at a greater risk of dying from non-cancer causes than from breast cancer. Factors such as pre-existing diseases like heart disease and osteoporosis are associated with this increased risk. The researchers also found that women with cancer cells in the lymph nodes ...
Researchers found 41 inaccurate statements on 18 websites, 5.2% of total analyzed web pages. Despite quality criteria, no combination could differentiate accurate from inaccurate content.
A new study found that 41 false statements appeared on 18 web pages (5.2%) and that websites with complementary or alternative medicine were 15.6 times more likely to have inaccuracies. The authors advise patients to be skeptical of online health information and consult a clinician before taking action.
A new study by Memorial Sloan Kettering Cancer Center found that risk-reducing salpingo-oophorectomy (RRSO) is associated with a 72% breast cancer risk reduction in women with BRCA2 mutations, compared to 38% for BRCA1 mutation carriers. The surgery also reduced the risk of gynecologic cancer by 85% in women with a BRCA1 mutation.
Researchers identified CDK10 as a key factor in breast cancer treatment resistance, which occurs earlier in tumors expressing low levels of the protein. The study also found that methylation of the CDK10 gene correlates with resistance.
A study by Dr. Catherine Sabiston found that breast cancer survivors who participated in dragon boat racing reported significantly improved physical and mental health. The social aspect of the activity provided a sense of community and empowerment, helping women cope with post-recovery trauma.
Research found women living in gentrifying neighborhoods in Cook County are at higher risk of distant-stage metastasis than those in similar non-gentrified areas. Disruption to social networks and access to healthcare services may contribute to the increased risk.
Researchers found that BRCA1 plays a role in regulating breast stem cells, which can develop into cancers. Women with BRCA1 mutations have a high incidence of breast cancer due to the unregulated proliferation of these stem cells.
Researchers analyzed data from nearly 30,000 women with breast cancer and found that female surgeons were more likely to prescribe post-surgical radiation therapy. Women who received radiation had a surgeon trained in the US or with an M.D. degree compared to a D.O. degree.
Researchers found Ki-67 expression associated with poorer disease-free survival, but not predictive of chemotherapy benefit. Pathology reports offer a reliable alternative for determining ER status in breast cancer trials.